The Myeloma Trial Finder lists clinical trials which are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.

It provides information about clinical trials in the UK. Trials included are not necessarily endorsed by Myeloma UK.

Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on 0800 980 3332

Recruitment to clinical trials may be paused at some hospitals due to the COVID-19 pandemic. Your healthcare team can provide additional details about recruitment to clinical trials in your area.

There are currently 24 open trials. In 127 locations

What is a Clinical Trial?

Step 2: Choose a Trial

There are currently 24 open trials

Step 3: View Details

Trial Title:

Improving the early detection of myeloma in smouldering myeloma patients (COSMOS)



Myeloma stage:


Trial phase:



A study looking at how and why smouldering myeloma progresses to active myeloma.



University College Hospital, London

Who can enter the study?

Who can enter the study?:

Smouldering myeloma patients who have been diagnosed for less than five years.


What's involved?

What's involved?:

This is an observational study therefore no drugs are being tested.

Patients who join the study will be monitored and followed up as normal by their healthcare team. Samples from routine blood or bone marrow tests will be shared with the study team.

The study team will use the samples to measure the number and type of genetic changes in the abnormal plasma cells responsible for smouldering myeloma and the number and function of the immune cells in blood and bone marrow.

For more information contact the research team or visit the study website.


Clinical Information

Clinical Information
(for Medical Professionals):

A UK wide observational study for smouldering myeloma patients to identify genetic and immune changes associated with progression to active myeloma. For more information contact the research team or visit the study website.


Find out more about Myeloma UK:


Do you want to talk to someone? Call our myeloma Infoline